Achillion Pharmaceuticals Inc (ACHN.O)
|Market Cap (Mil.):||$302.49|
|Shares Outstanding (Mil.):||96.64|
- Achillion Pharmaceuticals Inc said the U.S. Food and Drug Administration decided not to lift a clinical hold it had placed on the firm's hepatitis C drug, sovaprevir, leaving an uncertain fate for the company's most promising drug.
* Co says liver enzymes elevated in drug interaction with HIV drug
July 1 - Achillion Pharmaceuticals Inc said the U.S. Food and Drug Administration had placed a clinical hold on its hepatitis C drug sovaprevir after elevations in liver enzymes were noted in an early-stage study of the drug's interaction with an HIV drug.
|Pfizer Inc. (PFE.N)||$30.17||-0.08|
|Johnson & Johnson (JNJ.N)||$91.41||+0.25|
|Novartis AG (NOVN.VX)||CHF68.40||+0.05|
|Merck & Co., Inc. (MRK.N)||$48.43||+0.11|
|Roche Holding Ltd. (ROG.VX)||CHF234.80||-1.40|
|Abbott Laboratories (ABT.N)||$36.44||+0.15|
|AstraZeneca plc (AZN.L)||3,525.50p||+67.50|
|GlaxoSmithKline plc (GSK.L)||1,570.85p||0.00|
|Bristol-Myers Squibb Co (BMY.N)||$50.33||-0.22|
|Bristol-Myers Squibb Co (BMYMP.PK)||$873.04||+43.25|
Earnings vs. Estimates
Analyst Research Reports
Provider: New Constructs, LLC
Provider: Thomson Reuters Stock Report
Provider: ValuEngine, Inc.
Provider: Wright Reports
Achillion Pharmaceuticals Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.